Pharmacokinetics of digoxin. 1977

J E Doherty, and G V Dalrymple, and M L Murphy, and J J Kane, and J K Bissett, and N de Soyza

The pharmacokinetics of digoxin, the most frequently used digitalis preparation, are reviewed. The dominate serum turnover time is about 34 hours, and is not affected by the route of administration. Excretion is largely as unchanged digoxin in the urine and this excretion is compromised in renal failure. Serum levels of digoxin (determined by radioimmunoassay) are generally available and are useful clinically in assessment of both toxicity and the state of underdigitalization, even though significant overlap exists. Special problems are presented in patients with myocardial infarction, pulmonary heart disease, and thyroid disease.

UI MeSH Term Description Entries
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D007700 Kinetics The rate dynamics in chemical or physical systems.
D009200 Myocardial Contraction Contractile activity of the MYOCARDIUM. Heart Contractility,Inotropism, Cardiac,Cardiac Inotropism,Cardiac Inotropisms,Contractilities, Heart,Contractility, Heart,Contraction, Myocardial,Contractions, Myocardial,Heart Contractilities,Inotropisms, Cardiac,Myocardial Contractions
D009203 Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION). Cardiovascular Stroke,Heart Attack,Myocardial Infarct,Cardiovascular Strokes,Heart Attacks,Infarct, Myocardial,Infarction, Myocardial,Infarctions, Myocardial,Infarcts, Myocardial,Myocardial Infarctions,Myocardial Infarcts,Stroke, Cardiovascular,Strokes, Cardiovascular
D009765 Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
D011660 Pulmonary Heart Disease Hypertrophy and dilation of the RIGHT VENTRICLE of the heart that is caused by PULMONARY HYPERTENSION. This condition is often associated with pulmonary parenchymal or vascular diseases, such as CHRONIC OBSTRUCTIVE PULMONARY DISEASE and PULMONARY EMBOLISM. Cor Pulmonale,Disease, Pulmonary Heart,Diseases, Pulmonary Heart,Heart Disease, Pulmonary,Heart Diseases, Pulmonary,Pulmonary Heart Diseases
D004071 Digitalis Glycosides Glycosides from plants of the genus DIGITALIS. Some of these are useful as cardiotonic and anti-arrhythmia agents. Included also are semi-synthetic derivatives of the naturally occurring glycosides. The term has sometimes been used more broadly to include all CARDIAC GLYCOSIDES, but here is restricted to those related to Digitalis. Glycosides, Digitalis
D004077 Digoxin A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666) Digacin,Digitek,Digoregen,Digoxina Boehringer,Digoxine Nativelle,Dilanacin,Hemigoxine Nativelle,Lanacordin,Lanicor,Lanoxicaps,Lanoxin,Lanoxin-PG,Lenoxin,Mapluxin,Boehringer, Digoxina,Lanoxin PG,Nativelle, Digoxine,Nativelle, Hemigoxine
D006339 Heart Rate The number of times the HEART VENTRICLES contract per unit of time, usually per minute. Cardiac Rate,Chronotropism, Cardiac,Heart Rate Control,Heartbeat,Pulse Rate,Cardiac Chronotropy,Cardiac Chronotropism,Cardiac Rates,Chronotropy, Cardiac,Control, Heart Rate,Heart Rates,Heartbeats,Pulse Rates,Rate Control, Heart,Rate, Cardiac,Rate, Heart,Rate, Pulse
D000375 Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time. Senescence,Aging, Biological,Biological Aging

Related Publications

J E Doherty, and G V Dalrymple, and M L Murphy, and J J Kane, and J K Bissett, and N de Soyza
January 1977, Clinical pharmacokinetics,
J E Doherty, and G V Dalrymple, and M L Murphy, and J J Kane, and J K Bissett, and N de Soyza
February 1981, JAMA,
J E Doherty, and G V Dalrymple, and M L Murphy, and J J Kane, and J K Bissett, and N de Soyza
January 1982, Clinical and experimental dialysis and apheresis,
J E Doherty, and G V Dalrymple, and M L Murphy, and J J Kane, and J K Bissett, and N de Soyza
January 1983, European journal of clinical pharmacology,
J E Doherty, and G V Dalrymple, and M L Murphy, and J J Kane, and J K Bissett, and N de Soyza
October 1973, British medical journal,
J E Doherty, and G V Dalrymple, and M L Murphy, and J J Kane, and J K Bissett, and N de Soyza
January 1980, Clinical pharmacokinetics,
J E Doherty, and G V Dalrymple, and M L Murphy, and J J Kane, and J K Bissett, and N de Soyza
June 1983, Journal of veterinary pharmacology and therapeutics,
J E Doherty, and G V Dalrymple, and M L Murphy, and J J Kane, and J K Bissett, and N de Soyza
February 1993, Journal of clinical pharmacy and therapeutics,
J E Doherty, and G V Dalrymple, and M L Murphy, and J J Kane, and J K Bissett, and N de Soyza
January 1982, Pediatric pharmacology (New York, N.Y.),
J E Doherty, and G V Dalrymple, and M L Murphy, and J J Kane, and J K Bissett, and N de Soyza
July 1982, Polski tygodnik lekarski (Warsaw, Poland : 1960),
Copied contents to your clipboard!